Patient-Derived Ovarian Cancer Organoid Model

Ovarian cancer (OC) is the most lethal gynecologic malignancy, severely affecting female reproductive health around the world. Creative Biolabs keeps an eye on this disease and continuously develops optimum in vitro models like patient-derived ovarian cancer organoid models to support worldwide researchers’ drug discovery projects against ovarian cancer.

Limitations of Common Ovarian Cancer Models

Over the decades, common OC models include the cell culture model (monolayer and spheroids) or xenografts in OC-related research. However, these models have troubling limitations, such as therapeutic resistance and the gap between preclinical data and clinical efficacy. In addition, with low biological stability, the traditional cell culture fails to represent the clinical cancer spectrum and loses growth potential. On the other hand, although xenografts are an in vivo model, they are short of high-throughput drug screening potential and challenging to perform genetic manipulation. To improve the success rate of drug development, a suitable model that can address these tissues needs to be explored.

Advantages of Patient-derived Ovarian Cancer Organoid Models

Recently developed organoid model is used more and more in OC research. Like a miniature organ, it offers a special in vitro tool to monitor desired in vivo biological information. To date, many tumor organoid models have been successfully established to apply to cancer preclinical and clinical studies. Although not mature enough, patient-derived ovarian cancer organoid models demonstrate a series of unparallel advantages compared with common OC research techniques.

• Such models have a long term expansion capability, which is a magical feature. After all, they are still an in vitro model.
• Mimicking in vivo conditions has been difficult for in vitro models all along. Luckily, organoid models can do this easily.
• This type of model reflects tumor heterogeneity, which is important in predicting drug resistance and investigating effective treatments.
• They can well match with fast and efficient high-throughput drug screening.
• In modeling issue subtypes, such models can play an essential role.

Applications

Ovarian cancer organoids can be applied in much scientific research, such as studying the occurrence and development of OC, evaluating patient prognosis, establishing an organoid biobank, and identifying and testing new drugs (Liu, 2020). Such dynamic and novel technology opens up a bright future for research on malignant tumors and is expected to become one of the mainstream cancer research methods.

Fig.1 Applications of ovarian cancer organoids. (Creative Biolabs)

Related Service

Creative Biolabs is a global leader in providing 3D organoid models in response to the demands of the life sciences and pharmaceuticals. With an experienced research team and multiple-channel expert resources, we are willing to offer the reliable patient-derived ovarian cancer organoid model and related services along the science research path in the way you need. Don’t hesitate to contact us to discuss your project for professional technical support.

Related Sections:

• Patient-Derived Organoid (PDO) Model
• PDX-Derived Organoid (PDXO) Tumor Model